The assessment of antiangiogenic and antivascular therapies in early-stage clinical trials using magnetic resonance imaging: issues and recommendations

M O Leach; K M Brindle; J L Evelhoch; J R Griffiths; M R Horsman; A Jackson; G C Jayson; I R Judson; M V Knopp; R J Maxwell; D McIntyre; A R Padhani; P Price; R Rathbone; G J Rustin; P S Tofts; G M Tozer; W Vennart; J C Waterton; S R Williams; P Workman; Pharmacodynamic/Pharmacokinetic Technologies Advisory Committee, Drug Development Office, Cancer Research UK

doi:10.1038/sj.bjc.6602550

The assessment of antiangiogenic and antivascular therapies in early-stage clinical trials using magnetic resonance imaging: issues and recommendations

Br J Cancer. 2005 May 9;92(9):1599-610. doi: 10.1038/sj.bjc.6602550.

Affiliation

¹ Cancer Research UK Clinical Magnetic Resonance Research Group, Institute of Cancer Research, Royal Marsden Hospital, Sutton, Surrey, UK. martin.leach@icr.ac.uk

Abstract

Vascular and angiogenic processes provide an important target for novel cancer therapeutics. Dynamic contrast-enhanced magnetic resonance imaging is being used increasingly to noninvasively monitor the action of these therapeutics in early-stage clinical trials. This publication reports the outcome of a workshop that considered the methodology and design of magnetic resonance studies, recommending how this new tool might best be used.

Publication types

Guideline
Research Support, Non-U.S. Gov't

MeSH terms

Angiogenesis Inhibitors / therapeutic use*
Antineoplastic Agents / therapeutic use*
Clinical Trials as Topic
Evaluation Studies as Topic
Magnetic Resonance Imaging*
Neoplasms / blood supply*
Neoplasms / drug therapy*
Reproducibility of Results
Terminology as Topic

Substances

Angiogenesis Inhibitors
Antineoplastic Agents